[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337040-105":59,"doc-detail-337040-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mcrs1-sensitizes-t-celldependent-immunotherapy-by-augmenting-mhc-i-expression-in-solid-tumors","MCRS1 sensitizes T cell–dependent immunotherapy - by augmenting MHC-I expression in solid tumors","","Pancreatic cancer resists T cell–mediated anti-tumor immunity largely because antigen presentation is dampened, limiting immunotherapy effectiveness. Using high-throughput CRISPR activation, the transcriptional regulator MCRS1 is identified as a driver that increases sensitivity of mouse pancreatic cancer cells to T cell immunity in vitro and in vivo. MCRS1 binds YY1 to enhance chromatin accessibility and MHC-I gene expression, counteracting MHC-I suppression, activating anti-tumor T cells, and sensitizing tumors to α-PD-1. Elevated MCRS1 predicts greater T cell infiltration, longer survival in pancreatic cancer, and favorable α-PD-1 responses in lung cancer.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mcrs1-sensitizes-t-celldependent-immunotherapy-by-augmenting-mhc-i-expression-in-solid-tumors/337040/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mcrs1-sensitizes-t-celldependent-immunotherapy-by-augmenting-mhc-i-expression-in-solid-tumors/337040.png","ImageObject",300,407,{"name":92,"@type":93},"Seraphina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is T cell–mediated immunotherapy often ineffective in pancreatic cancer?","Question",{"text":112,"@type":113},"Because antigen presentation is dampened, cancer cells reduce tumor recognition and suppress T cell responses within the tumor microenvironment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role does MCRS1 play in sensitizing cancer cells to T cell immunity?",{"text":117,"@type":113},"MCRS1 significantly increases sensitivity by interacting with YY1 to enhance chromatin accessibility and upregulate MHC-I gene expression, counteracting MHC-I suppression.",{"name":119,"@type":110,"acceptedAnswer":120},"How does MCRS1 affect treatment response to α-PD-1?",{"text":121,"@type":113},"Elevated MCRS1 activates anti-tumor T cells and sensitizes mouse pancreatic cancer to α-PD-1 therapy, and high MCRS1 expression is associated with favorable α-PD-1 responses in lung cancer patients.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337040,1790144790,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":41,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","ARTICLE  \nMCRS1 sensitizes T cell–dependent immunotherapy by augmenting MHC-I expression in solid tumors  \nXue Li1*􀀁, Han Yi1*􀀁, Zheyu Jin1*􀀁, Kaitao Jiang1*􀀁, Kangkang Xue1􀀁, Jin Wang2􀀁, Yuping Qian2􀀁, Qian Xiang3􀀁, Sijing Zhu1􀀁, Runhe Yan1􀀁 , Yulong Yang2􀀁, Shenfei Sun4􀀁, Kai Li1,5􀀁, Zichu Zhou1􀀁, Wei Yu1􀀁, Ning Jiang1􀀁, Chen Ding1,5􀀁, Xinhua Lin4􀀁, Jiang Zhong1􀀁, Yuchao Dong3􀀁 , Yanfang Liu2,6􀀁, and Xiaofei Yu1,7􀀁  \nDampened antigen presentation underscores the resistance of pancreatic cancer to T cell–mediated anti-tumor immunity, rendering immunotherapy largely ineffective. By high-throughput CRISPR activation perturbation, we discovered that the transcriptional regulator MCRS1 significantly augmented the sensitivity of mouse pancreatic cancer cells to T cell immunity in vitro and in vivo. Mechanistically, MCRS1 interacted with the transcription factor and genome organizer YY1 to coordinately increase the chromatin accessibility and expression of MHC-I genes. Elevated MCRS1 subverted MHC-I suppression and activated anti-tumor T cells, which sensitized mouse pancreatic cancer to α-PD-1 therapy. Remarkably, high MCRS1 expression was associated with increased T cell infiltration and extended survival of patients with pancreatic cancer and was predictive of favorable responses to α-PD-1 therapy in patients with lung cancer. Together, our study uncovers that MCRS1 sensitizes cancer cells to T cell immunity by transcriptionally subverting MHC-I suppression, which enhances the effectiveness of α-PD-1 therapy in mice and humans, paving the way to further improve immunotherapy against solid tumors.  \nIntroduction  \nT cell immunity is the body’s crucial surveillance mechanism against cancerous cells, which underpins the success of newly emerged immunotherapy and contributes to the effectiveness of conventional chemotherapy and radiotherapy (Gotwals et al., 2017; Metcalf et al., 2021; Wang et al., 2024) . Cancer cells have devised various strategies to evade T cell–mediated anti-tumor immunity (Mellman et al., 2023), including reducing tumor recognition by dampening antigen presentation and suppressing T cell responses by creating an immune inhibitory tumor microenvironment. These evasion mechanisms collectively render cancer cells insensitive to T cell immunity in solid tumors, representing a significant challenge for immunotherapy such as PD-1 blockade. Therefore, identifying factors that can sensitize or predict T cell responses against solid tumors would pave the way to further improve the efficacies of cancer treatment.  \nTumor recognition is a prerequisite for T cell–mediated antitumor immunity and critically depends upon tumor antigens presented by the major histocompatibility complex (MHC)-I (Waldman et al., 2020) . Once primed by antigen-presenting cells, cytotoxic effector T cells can recognize tumor antigens  \npresented by MHC-I on the tumor cell surface, resulting in antigen-dependent killing of tumor cells. Unsurprisingly, cancer cells could actively suppress antigen presentation by inducing MHC-I degradation and downregulating or mutating genes involved in MHC-I–mediated antigen presentation (Gettinger et al., 2017; Yamamoto et al., 2020b) . Indeed, effective immunotherapy, such as immune checkpoint blockade (ICB), relies on the pre-existing T cell immunity in the tumor (Galon and Bruni, 2019), reinforcing the importance of antigen presentation and tumor recognition. Concordantly, targeting the MHC-I degradation pathways has been found to augment antigen presentation and sensitize tumor clearing by T cells in multiple tumor models (Chen et al., 2023; Liu et al., 2020; Yamamoto et al., 2020b) . However, this approach could be limited by the expression suppression of the MHC-I machinery in some cancers, and complementary strategies to elevate basal MHC-I expression may further sensitize cancer cells to T cell–mediated antitumor immunity.  \nPancreatic cancer exhibits the highest mortality rate of all major cancers (Johnso","cbCaijm0eOln0iUA","https://ap.wps.com/l/cbCaijm0eOln0iUA","pdf",8122645,"English","# Introduction\n## T cell immunity and antigen presentation\n## Immune evasion by tumors\n## Rationale for enhancing MHC-I expression","[{\"question\":\"Why is T cell–mediated immunotherapy often ineffective in pancreatic cancer?\",\"answer\":\"Because antigen presentation is dampened, cancer cells reduce tumor recognition and suppress T cell responses within the tumor microenvironment.\"},{\"question\":\"What role does MCRS1 play in sensitizing cancer cells to T cell immunity?\",\"answer\":\"MCRS1 significantly increases sensitivity by interacting with YY1 to enhance chromatin accessibility and upregulate MHC-I gene expression, counteracting MHC-I suppression.\"},{\"question\":\"How does MCRS1 affect treatment response to α-PD-1?\",\"answer\":\"Elevated MCRS1 activates anti-tumor T cells and sensitizes mouse pancreatic cancer to α-PD-1 therapy, and high MCRS1 expression is associated with favorable α-PD-1 responses in lung cancer patients.\"}]","MCRS1 sensitizes T cell–dependent immunotherapy - by augmenting MHC-I expression in solid tumors | PDF",1790017483,76,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/71d872b9ae9de772ded6375e8ae155bb.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0674a704c37866a63e7055d401cb330b.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd4247c1e8d828d0e6b4da38c3b68b17.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d053e423052fc7ebe378b166d428a106.webp",980,1268]